Abstract
Lung inflammation is a hallmark of Coronavirus disease 2019 (COVID-19) in severely ill patients and the pathophysiology of disease is thought to be immune-mediated. Mast cells (MCs) are polyfunctional immune cells present in the airways, where they respond to certain viruses and allergens, often promoting inflammation. We observed widespread degranulation of MCs during acute and unresolved airway inflammation in SARS-CoV-2-infected mice and non-human primates. In humans, transcriptional changes in patients requiring oxygen supplementation also implicated cells with a MC phenotype. MC activation in humans was confirmed, through detection of the MC-specific protease, chymase, levels of which were significantly correlated with disease severity. These results support the association of MC activation with severe COVID-19, suggesting potential strategies for intervention.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
: Duke-NUS Start-up funding to ALS; COVID19RF3-0033 to ALS and LH and National Medical Research Council, Singapore COVID19RF2-0001 to DEA; R21, and NIH grants 1R21NS117973-01, 1R56HL126891-01, and a Duke School of Medicine Health Scholar Award to JK.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The data associated with human transcriptional responses was approved by the SingHealth Combined Institutional Review Board (CIRB 2017/2374). Additional patients with confirmed SARS-CoV-2 infection in Singapore were recruited in accordance with protocols approved by the intuitional IRB, DSRB domain E, (#2020/00120) and informed consent was taken from all patients. This study was approved by the National University of Singapore under NUS-IRB-2021-186. Patients from the Duke University Health System (DUHS) or the Durham Veterans Affairs Health System (DVAHS) were enrolled into the IRB-approved protocol, Molecular and Epidemiological Study of Suspected Infection (MESSI, Pro00100241).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data needed to evaluate the conclusions are included in the manuscript and additional data maybe requested.
